CT-CSPC@EC2701A

CSPC Pharmaceutical Group Releases 2026 Q1 Report: Revenue and Net Profit Fall, Stock Price Drops Over 5%

UBS Maintains Buy Rating on CSPC, Anticipates $1.2B AstraZeneca Payment in Q2 2026

CSPC Group Q1 Revenue 6.47 Billion, R&D Spend 1.4 Billion

CSPC PHARMA released FY2026 Q1 earnings on May 27 Pre-Market (BJT), actual revenue HKD 7.33 B (forecast HKD 7.533 B), actual EPS HKD 0.0854 (forecast HKD 0.1303)

CSPC's Lansoprazole Enteric-coated Capsules Obtain NMPA Registration Approval

Huitianfu Fund reduces 9.824 million shares of CSPC Pharmaceutical on May 19, raising approx 73.22 million HKD

CSPC Pharma's Enric (Ustekinumab Injection) Approved for Psoriasis Treatment

Sinopharm New World Subsidiary Approved to Market Ustekinumab Injection

UBS Upgrades CSPC Pharmaceutical to Buy, Cites AI Drug R&D and Valuation Potential

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

Jiayi Group's BD Project MAT2A Inhibitor Downgraded by BeiGene

Jade Pharmaceutical Group Develops Online Infrared Spectroscopy Technology for Oligonucleotide Solid-Phase Deprotection Process

Huitianfu Fund Management Co. Increased Its Holdings in CSPC Group

Ji Pharmacy Group's Amphotericin B Liposome Injection Approved in the EU

Stone Pharmaceutical's Antibody-Drug Conjugate SYS6051 Approved for Clinical Trials in US and China

Sino Pharm Group Releases 2025 Annual Report

CNS Pharma Revenue Grows 40.82% in Q1 2026, Net Loss Expands by 248.88%

Sino-Pharma Group's New Drug SYH2095 Receives FDA Approval for Clinical Trials

JOLIMARK

MAN YUE TECH

RISECOMM GP

DEEPZERO

WKK INTL (HOLD)

PANGAEA CONNECT

SMIT

TIANLI HOLDINGS

PROSPER FUTURE

KEEN OCEAN

01093

562050

159506

159570

513700

520690

CSPC Pharmaceutical Group's shareholders approved all resolutions at the AGM on May 28, 2026, including the 2025 audited financial statements and a final dividend of HK15 cents per share. The re-election of directors and the reappointment of Deloitte as auditor were also supported, despite some opposition. A special resolution to adopt new Articles of Association was passed, reflecting governance updates. The stock has a Buy rating with a target price of HK$13.05.

Tip Ranks

CSPC PHARMA

Hwabao WP CSI Pharmaceuticals ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

CSPC Pharmaceutical Wins Shareholder Backing for All AGM Resolutions

UBS reported that CSPC PHARMA's 1Q26 net profit fell 41.8% YoY to RMB860 million, missing forecasts, while revenue was RMB6.5 billion, down 7.8% YoY but exceeding expectations. The bank maintains a Buy rating with a target price of HKD10.9, citing strong drug sales growth and limited impact from recent policy changes. The USD1.2 billion payment from AstraZeneca is expected in 2Q26.

AASTOCKS News

UBS Group AG

AstraZeneca

AstraZeneca PLC

UBS: CSPC PHARMA  1Q26 Net Profit Misses; Revenue Beats; Rated Buy

CSPC Pharmaceutical Group's shares dropped over 10% in afternoon trading after reporting a 41.8% decline in Q1 net profit compared to last year. The company is listed on the Hong Kong Stock Exchange under ticker.

CoinLive

STOCKS | CSPC Pharmaceutical Group Shares Drop Over 10% as Q1 Net Profit Falls 41.8%

510660

512010

CSPC Pharmaceutical Group reported a 7.8% decline in Q1 2026 revenue to RMB6.47 billion, with profit attributable to shareholders dropping 41.8% to RMB860 million, primarily due to a significant decrease in licence fee income. Finished drug sales grew 6.2%, but overall revenue fell 5%. Analysts maintain a Buy rating on the stock with a price target of HK$13.05.

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

CSPC Pharmaceutical Profit Slumps on Sharp Drop in Licence Fee Income

CSPC PHARMA reported a 40.3% YoY decline in basic profit for 1Q26, totaling RMB842 million. Revenue fell 7.8% YoY to RMB6.465 billion, with net profit down 41.8% to RMB860 million. The finished drug business generated RMB5.224 billion, a 5% decrease YoY, largely due to reduced licensing fee income. R&D expenses rose 7.7% YoY to RMB1.403 billion, representing 26.8% of finished drug revenue.

CSPC PHARMA  1Q26 Basic Profit Falls 40.3% YoY to RMB842 million

CONCORD HC GPannounced a proposal to issue HKD68 million in convertible bonds to a subsidiary of CSPC PHARMA. After expenses, net proceeds are expected to be around HKD63.1 million. Approximately 70% of the funds will be used to repay loans, while 30% will support working capital. The bonds will convert into 40 million H shares, equating to about 4.86% of the enlarged total issued shares.

CONCORD HC GP

CONCORD HC GP  Proposes to Issue HKD68 Million Convertible Bonds to CSPC PHARMA

CSPC Pharmaceutical Group has received FDA approval for its SYS6051 antibody-drug conjugate, allowing clinical trials in the U.S. It also secured clearance from China's National Medical Products Administration for trials in advanced solid tumors. Preclinical studies indicate strong anti-tumor activity, enhancing CSPC's oncology pipeline and competitive position. Analysts rate the stock (HK:1093) as a Buy with a price target of HK$13.05. CSPC focuses on innovative therapies and operates globally, listed on the Hong Kong Stock Exchange with a market cap of HK$101.3B.

CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate

159837

516500

CSPC Pharmaceutical Group reported a 40.82% year-on-year revenue increase to RMB 664.6 million for Q1 2026, but its net loss deepened to RMB 93.9 million. The company cautioned that these figures are unaudited and pertain only to its subsidiary, CSPC Innovation Pharmaceutical. Despite stable total assets, profitability metrics worsened, indicating potential cost pressures. Analysts maintain a Buy rating on the stock (HK:1093) with a price target of HK$13.05.

CT-CSPC@EC2701A(29488.HK)

CSPC Pharmaceutical Wins Shareholder Backing for All AGM Resolutions

UBS: CSPC PHARMA 1Q26 Net Profit Misses; Revenue Beats; Rated Buy

STOCKS | CSPC Pharmaceutical Group Shares Drop Over 10% as Q1 Net Profit Falls 41.8%

CSPC Pharmaceutical Profit Slumps on Sharp Drop in Licence Fee Income

CSPC PHARMA 1Q26 Basic Profit Falls 40.3% YoY to RMB842 million

CONCORD HC GP Proposes to Issue HKD68 Million Convertible Bonds to CSPC PHARMA

CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate

CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026